

6. 田中ゆり子、種市麻衣子、笠井道之、垣内史堂、内田哲也：不飽和脂肪酸からなるリポソームの表面に結合した抗原により誘導されるクロスプレゼンテーションの機序 第 37 回日本免疫学会総会、2007 年 12 月

7. 大野悟史、高山俊輔、守屋修、種市麻衣子、小田洋、林秀徳、赤塚俊隆、内田哲也、松井政則：SARS ウイルス特異的細胞傷害性 T 細胞 (CTL) に対するエピトープの決定とペプチド結合リポソームによる CTL の誘導 第 128 回日本薬学会、2008 年 3 月

**G. 知的財産権の出願・登録状況（予定を含む。）**

1. 特許取得  
該当なし。
2. 実用新案登録  
該当なし。
3. その他  
該当なし。

図一 リポソーム結合OVAペプチドによるCTLの誘導









図-2 リポソーム結合OVAペプチドによるCTLの誘導における  
GK1.5の影響



GK1.5 (-)



GK1.5 (+)



厚生労働科学研究費補助金（医療機器開発推進研究事業）  
分担研究報告書

リン脂質の安全性の検討およびリポソーム作製

分担研究者 小田 洋 日油株式会社 DDS 研究所処方グループ グループリーダー

**研究要旨** 日油株式会社では、1990 年代初頭より GMP グレードのリン脂質を世界に向けて供給し、高い評価を得ている。このリン脂質の構成成分であるオレイン酸（日油エキストラオレイン 99）は純度が非常に高い。これまでの研究の結果、この不純物が少ないという特長は安全性につながるということが確認されている。本研究では、安全性に優れ、脂質組成を選択することによりアジュバント効果を高めることのできるリポソームを用いて、現在開発が急がれているウイルス疾患に対するワクチン開発を試みている。

**A. 研究目的**

本研究では鳥インフルエンザ、SARS、C 型肝炎に対するワクチン開発を目指しており、より効率的なワクチン開発のために、リポソームの安全性の検討を行い、研究に必要なリポソームの供給を行うことを目的とする。

**B. 研究方法**

ウイルス疾患に対するワクチンに最適である脂質組成のリポソームの安全性の検討、及びウイルス由来ペプチドを結合するためのリポソームの作製を行った。

**C. 研究結果**

日油エキストラオレイン 99 を構成成分とするリポソームは安全性に優れ、細胞毒性、溶血性、急性毒性が低いこと、アレルギー様反応を起こしにくいことが確認された。また、高病原性鳥インフルエンザ、SARS、C 型肝炎の各ウイルスを構成する蛋白に由来するペプチドを結合するための DDS 誘導リポソームを作製し、供給した。

**D. 考察**

ワクチンの安全性は実用化を考える上で重要であり、本研究に使用しているリポソームはその点で非常に優れている。

**E. 結論**

キャリアーとしての有効性および安全性に優れたリポソームを本研究に供給し、開発が急がれているウイルス疾患に対するワクチン開発を目指した。

**F. 研究発表**

1. 論文発表

Nagata T, Toyota T, Ishigaki H, Ichihashi T, Kajino K, Kashima Y, Itoh Y, Mori M, Oda H, Yamamura H, Taneichi M, Uchida T, Ogasawara K. Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses. *Vaccine*. 2007;25: 4914-4921.

2. 学会発表

なし。

**G. 知的財産権の出願・登録状況（予定を含む。）**

1. 特許取得  
該当なし。
2. 実用新案登録  
該当なし。
3. その他  
該当なし。

### III. 研究成果の刊行に関する一覧表

書籍

該当なし

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tetsuya Uchida Maiko Taneichi	Clinical application of surface-linked liposomal antigens	Mini-Reviews in Clinical Chemistry	8	184-192	2008
Nagata T, Toyota T, Ishigaki H, Ichihashi T, Kajino K, Kashima Y, Itoh T, Mori M, Oda H, Yamamura H, Taneichi M, Uchida T, Ogasawara K.	Peptide coupled to the surface of a kind of liposome protect infection of influenza viruses	Vaccine	25	4914-4921	2007
Masanori Matsui	Roles of the novel interleukin-12-associated cytokine, interleukin-23, in the regulation of T-cell-mediated immunity	Hepatology Research	37	S310-318	2007
Kohyama S, Ohno S, Isoda A, Moriya O, Belladonna ML, Hayashi H, Iwakura Y, Yoshimoto T, Akatsuka T, Matsui M	IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17	Journal of Immunology	179	3917-3925	2007

Ueha S, Murai M, Yoneyama H, Kitabatake M, Imai T, Shimaoka T, Yonehara S, Ishikawa S, Matsushima K.	Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus- tumor effects	Journal of Leukocyte Biology	81	176-185	2007
--	---	------------------------------------	----	---------	------



#### IV. 研究成果の刊行物・別刷

## Clinical Application of Surface-Linked Liposomal Antigens

T. Uchida\* and M. Taneichi

Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-city, Tokyo 208-0011, Japan

**Abstract:** The potential usefulness of surface-linked liposomal antigens for application to vaccine development was investigated. During the course of this investigation, a significant difference was observed in the recognition of liposomal antigens by antigen-presenting cells (APCs) between liposomes with different lipid components, and this difference was closely correlated with the adjuvant activity of liposomes. In addition to this "quantitative" difference between liposomes with differential lipid components, a "qualitative" difference (i.e., a differential ability to induce cross-presentation) was also observed between liposomes with different lipid components. Although the precise mechanism underlying this difference is currently unclear, the significant difference in membrane mobility observed between these liposomes might affect their ability to induce cross-presentation. Thus, surface-linked liposomal antigens may be applicable for the development of vaccines with minimal allergic side effects and for a novel protocol of allergen immunotherapy. In addition, by utilizing their ability to induce cross-presentation, surface-linked liposomal antigens could be used to develop virus vaccines that induce a cytotoxic T-cell (CTL) response, as well as tumor vaccine preparations that present tumor antigens to APCs and induce effective antitumor responses. These data suggest that differential lipid components in liposomes lead to differential processing and presentation of liposomal antigens in APCs.

**Key Words:** Liposome, IgE, allergy, vaccine, cross-presentation, antitumor immunity.

### INTRODUCTION

Adjuvants are indispensable in vaccines, especially for antigens with weak immunogenicity. However, the currently used aluminum adjuvants are known to stimulate only humoral responses [1] and are also known to induce IgE antibody production, which elicits an allergic response in some individuals following vaccination [2]. Therefore, there is need of improved adjuvants suitable for clinical use. Among the candidates for adjuvants for novel vaccines, liposomes are garnering attention as antigen carriers (vehicles) because they are known to act as powerful adjuvants when physically associated with a protein antigen [3-6]. Most of the liposomal vaccines proposed have been prepared by antigen entrapment within the aqueous lumen of liposomes [7]. However, it is known that encapsulated and surface-linked liposomal antigens induce differential immune responses in both humoral- [8] and cell-mediated [9] immunity. We previously reported that surface-linked liposomal antigens induced IgE-selective unresponsiveness [10]. The results were consistent even when different procedures for coupling antigens with liposomes [11], or for producing liposomes with different lipid components [12], were employed. During the course of an investigation intended to clarify the mechanism of IgE-selective unresponsiveness induced by surface-coupled liposomal antigens, we discovered an alternative approach to regulating the production of IgE, one that is independent of the activity of T cells [13]. The IgE-selective unresponsiveness induced by the liposomal antigen involved direct effects on IgE, but not IgG switching *in vivo*. Thus, surface-linked

liposomal antigen is expected to be applicable for the development of a novel vaccine that induces minimal IgE synthesis. Moreover, given the relatively low allergic response to and increased antigenicity of the allergen, this form of antigen preparation would be applicable for allergen immunotherapy [14, 15]. In addition, we recently found that, by choosing lipid components for liposomes, surface-coupled liposomal antigens are cross-presented to CD8<sup>+</sup> T cells *via* MHC class I [16]. Therefore, surface-linked liposomal antigens might be applicable for the development of tumor vaccines to present tumor antigens to antigen-presenting cells (APCs) and induce antitumor responses, and for the development of virus vaccines to induce cytotoxic T-cells (CTLs) to eliminate virus-infected host cells.


In this manuscript, data indicating the correlation existing between the lipid component of liposomes and the immune response induced by surface-linked liposomal antigens are summarized and the potential of surface-linked liposomal antigens for clinical application is discussed.

### LIPOSOMES WITH DIFFERENTIAL LIPID COMPONENTS EXERT DIFFERENTIAL ADJUVANTICITY IN ANTIGEN-LIPOSOME CONJUGATES *VIA* DIFFERENTIAL RECOGNITION BY MACROPHAGES

Liposomes having differential lipid components were demonstrated to display differential adjuvant effects when antigen was coupled with liposomes *via* glutaraldehyde [12]. Antigen-liposome conjugates prepared using liposomes having differential lipid components were added to a macrophage culture, and phagocytosis and the digestion of liposome-coupled antigen by the macrophages were then investigated [17]. Mice were immunized with ovalbumin (OVA)-liposome conjugates which were made using "stearoyl" or


\*Address correspondence to this author at the Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-city, Tokyo 208-0011, Japan; Tel: +81-42-561-0771; Fax: +81-42-562-7892; E-mail: tuchida@nih.go.jp

"oleoyl" liposomes. Fig. (1) shows the serum anti-OVA IgG titers six weeks after the primary immunization with OVA-liposome conjugates or with plain OVA solution. The levels




**Fig. (1).** Anti-OVA IgG antibody production in mice immunized with OVA-liposome conjugates. BALB/c mice were immunized with OVA-liposome conjugates made using "stearoyl" or "oleoyl" liposomes or with plain OVA solution at 0 and 4 weeks. Six weeks after primary immunization, the mice were bled from the tail vein, and serum anti-OVA IgG was measured. Data represent the mean and SE of five mice per group. Asterisk, significant ( $p < 0.01$ ) difference as compared with the "stearoyl" group.

of anti-OVA IgG antibody production induced by two OVA-liposome conjugates were significantly different; OVA-liposome conjugates made using the "oleoyl" liposome induced a more than ten-fold higher level of anti-OVA IgG production compared with that induced by the OVA-liposome conjugates made using "stearoyl" liposomes. The same dose of plain OVA solution induced a far lower level of anti-OVA IgG antibody production as compared with that induced by OVA-liposome conjugates. In order to examine if the differential adjuvant effects between the two liposome preparations observed in the above experiment were due to differential recognition of liposomal antigens by antigen-presenting cells, phagocytosis of OVA-liposome conjugates by macrophages was investigated by adding fluorescence-labeled OVA coupled with "stearoyl" or "oleoyl" liposomes to the macrophage culture. Fig. (2) shows the fluorescence intensity of the macrophages cultured for 60 min with OVA-liposome conjugates. More OVA was incorporated when OVA was coupled to "oleoyl" liposomes than when OVA was coupled to "stearoyl" liposomes. In order to compare the processing of OVA coupled either with "stearoyl" or "oleoyl" liposomes by macrophages, the fluorescence intensity of the macrophages was investigated by adding DQ-OVA-coupled liposomes to the macrophage culture. DQ<sup>TM</sup>-OVA (Molecular Probes, Eugene, OR) exhibits green fluorescence upon proteolytic degradation. Fig. (3) shows the results of the FACS analysis at 60 min after the addition of OVA-liposome conjugates to the culture. It appeared that the amount of OVA processed by macrophages in 60 min was greater when OVA was coupled to the "oleoyl" liposomes than when OVA was coupled to the "stearoyl" liposomes.



**Fig. (2).** Phagocytosis of OVA-liposome conjugates by macrophages. Fluorescence-labeled OVA was coupled to either "stearoyl" or "oleoyl" liposomes and added to the culture of macrophages. Macrophages recovered from the culture were analyzed using flow cytometry.



**Fig. (3).** Digestion of liposome-coupled OVA by macrophages. "stearoyl" or "oleoyl" liposomes coupled with DQ-OVA were added to the macrophage culture. Sixty minutes after the onset of the culture, the macrophages were recovered and analyzed using flow cytometry.

Antigen presentation by macrophages to an antigen-specific T-cell clone was further investigated using the same conjugates. Macrophages were cultured in the presence of OVA-liposome conjugates prior to the co-culture with the OVA-specific T-cell clone, 42-6A, and the IL-2 production by the T-cell clone was monitored. Fig. (4) shows the amount of IL-2 in the culture supernatant. A significantly higher level of IL-2 production was observed when the macrophages were pre-cultured with OVA-liposomes made using "oleoyl" liposomes. The amount of IL-2 was comparable to that when 800 µg/ml of plain OVA was added to the culture, although the amount of OVA in the culture to which OVA-liposome conjugates were added was 32 µg/ml. However, the addition of 32 µg of plain OVA to the culture resulted in production of a far lesser amount of IL-2. Although a substantial amount of IL-2 was produced when the macrophages were pre-cultured with OVA-liposome conjugates made using "stearoyl" liposomes, the IL-2 level was still more than ten-fold less than that in the "oleoyl" liposome group.




Fig. (4). Antigen presentation by macrophages pulsed with OVA-liposomes. Macrophages pre-incubated with OVA-liposomes were co-cultured with an OVA-specific T-cell clone. Data represent the mean IL-2 concentration and the SE of the culture supernatant in triplicate cultures. Asterisk, significant ( $p < 0.01$ ) difference as compared with the "stearoyl" group. Two asterisks, significant ( $p < 0.01$ ) difference as compared with the other groups.

Thus, these results clearly demonstrated that the adjuvant activity of liposomes observed primarily *in vivo* was closely correlated with the recognition of antigen-liposome conjugates and the presentation of liposome-coupled antigen by macrophages, suggesting that the adjuvant effects of liposomes are exerted at the beginning of the immune response, i.e., upon recognition of the antigen by antigen-presenting cells.

#### CHOLESTEROL INCLUSION IN LIPOSOMES AFFECTS INDUCTION OF ANTIGEN-SPECIFIC IGG AND IGE ANTIBODY PRODUCTION

In a study in which the induction of OVA-specific antibody production was investigated in mice by OVA-liposome conjugates made using four different lipid components [12], the highest titer of anti-OVA IgG was observed in mice immunized with OVA-liposomes made using liposomes with the highest membrane fluidity, suggesting that the membrane fluidity of liposomes affects their adjuvant effect. Here, liposomes with five different cholesterol inclusions, ranging from 0% to 43% of the total lipid, were made, and the induction of OVA-specific antibody production by OVA-liposome conjugates was compared among these liposome preparations [18].

In contrast to the results in the previous study [12], liposomes that contained no cholesterol and possessed the lowest membrane fluidity demonstrated the highest adjuvant effect for the induction of IgG antibody production. A significant difference was observed in the degree of fluorescence polarization among liposomes with different cholesterol inclusions (Fig. 5a). The increase in fluorescence polarization values can be interpreted as the result of a decrease in mobility of the hydrophobic region of phospholipid bilayers in the membranes. The results suggest that the membrane fluidity of liposomes correlated well with the amount of cho-

lesterol contained, and liposomes containing no cholesterol showed the lowest membrane fluidity. Liposomes in Fig. (5a) were then coupled with OVA and inoculated into mice. The level of anti-OVA IgG antibody production was correlated with the amount of cholesterol included in the liposomes (Fig. 5b), and OVA-liposome conjugates prepared




Fig. (5). a: Degree of fluorescence polarization in the liposomes with five different cholesterol inclusions. The degree of fluorescence polarization at 37°C was calculated. Data represent the mean and SE of the triplicate measurements. Asterisk, significant ( $p < 0.01$ ) difference.

b: Anti-OVA antibody production in mice immunized with OVA-liposome conjugates made using liposomes with five different cholesterol inclusions. Six weeks after primary immunization, the mice were bled from the tail vein, and the serum anti-OVA IgG were measured. Data represent the mean and SE of five mice per group. Asterisk, significant ( $p < 0.01$ ) difference.

using liposomes that contained no cholesterol induced the highest level of anti-OVA IgG antibody production. In addition, when the liposomes with four different lipid compositions were used, OVA-liposome conjugates made using liposomes that did not contain cholesterol induced significantly higher levels of anti-OVA IgG antibody production than did those made using liposomes that contained cholesterol (Fig. 6a), and, furthermore, the conjugates with no cholesterol induced production of a substantial amount of anti-OVA IgE, except in the case of "palmitoyl" liposomes (Fig. 6b).




Fig. (6). Anti-OVA antibody production in mice immunized with OVA-liposome conjugates made using liposomes with four different lipid formulations with (□) or without (■) cholesterol. Six weeks after primary immunization, the mice were bled from the tail vein, and serum anti-OVA antibodies were measured. a, IgG. b, IgE. Data represent the mean and SE of five mice per group. Asterisk, significant ( $p < 0.01$ ) difference as compared with liposomes of the same formulation containing cholesterol. ND, not detected.

Unexpectedly, the OVA-liposome conjugates made using liposomes containing no cholesterol induced production of a substantial amount of anti-OVA IgE, except in the "palmitoyl" liposome group. It is unlikely that the level of IgE production in those groups was related to the titer of IgG antibody production, since in mice immunized with OVA-liposome conjugates prepared using "oleoyl" liposomes, IgE antibody production was induced only in the group of no-cholesterol liposomes, although a similar level of IgG antibody production was induced in both the "oleoyl" and "stearoyl" liposome groups regardless of the presence or absence of cholesterol in liposomes. By the inclusion of cholesterol, liposomes might be made more resistant to disintegration and biological degradation [19]. Perhaps the change in the stability of liposomes caused by cholesterol inclusion affects both adjuvanticity and the capacity to induce IgE-selective unresponsiveness by antigen-coupled liposomes. Both IL-4 and IL-13 are known to play a key role in the induction of IgE antibody production [20]. However, since the CD4<sup>+</sup> T cells of mice immunized with OVA-liposome conjugates produced IL-4 upon *in vitro* stimulation with OVA (data not shown), regardless of *in vivo* IgE production, antigen-specific IL-4 production by T cells did not participate in the regulation of IgE production in mice immunized with OVA-liposome conjugates.

Thus, these results suggest that cholesterol inclusion in liposomes affects both the adjuvanticity for IgG production and the regulatory effects on IgE synthesis by the coupling of antigens to the surface of liposomes.

#### INCLUSION OF PHOSPHATIDYLSERINE IN LIPOSOMES INCREASES THEIR ADJUVANTICITY

Exposure of phosphatidyl serine on apoptotic cells is known to result in the enhanced recognition of apoptotic cells by phagocytes [21]. By the inclusion of phosphatidyl serine in the lipid component of liposomes, increased liposome-immune adjuvant activity was expected. Two different liposome preparations containing either phosphatidyl serine (PS-liposome) or phosphatidyl choline (PC-liposome) were made, and macrophage recognition, processing, and antigen presentation of surface-coupled liposomal antigen were compared between them [22].

When OVA-liposome conjugates were added to a culture of macrophages, enhanced recognition and processing of OVA by the macrophages were observed by the inclusion of phosphatidyl serine in the liposomes. The phagocytosis of OVA-liposome conjugates by macrophages was investigated by adding fluorescence-labeled OVA coupled with PC- or PS-liposomes to the macrophage culture. FACS analysis was performed 60 min after the addition of OVA-liposome conjugates to the macrophage culture. Fig. (7) shows the fluorescence intensity of macrophages cultured for 60 min with the OVA-liposome conjugates. More OVA was incorporated into the macrophages when the OVA was coupled to PS-liposomes (OVA-PS-liposome) than when OVA was coupled to PC-liposomes (OVA-PC-liposome). The results correlated well with those regarding the macrophage antigen presentation of liposome-coupled OVA. Macrophages were cultured overnight in the presence of OVA-liposome conjugates prior to co-culture with the OVA-specific T-cell clone,




Fig. (7). Phagocytosis of OVA-liposome conjugates by macrophages. Fluorescence-labeled OVA was coupled to either PC-liposomes (PC) or PS-liposomes (PS) and added to a culture of macrophages. Macrophages recovered from the culture were analyzed using flow cytometry.

42-6A. IL-2 production by the T-cell clone was then monitored. Fig. (8) shows the amount of IL-2 in the culture supernatant. A significantly high level of IL-2 production was observed when the macrophages were pre-cultured with OVA-PS-liposomes. The amount of OVA in the culture to which the OVA-liposome conjugates were added was 32  $\mu\text{g/ml}$ . However, the addition of 32  $\mu\text{g/ml}$  of plain OVA to the culture resulted in no or very low production of IL-2. Although a significant level of IL-2 was produced when the macrophages were pre-cultured with OVA-PC-liposomes, the amount of IL-2 was more than three-fold lower than that produced when PS-liposomes were added to the culture.

Furthermore, *in vivo* immunization in mice with OVA-liposome conjugates made using PS-liposomes induced a significantly higher level of anti-OVA IgG antibody production than was induced by OVA-liposome conjugates made using PC-liposomes (Fig. 9). IgE-selective unresponsiveness was induced by OVA-liposome conjugates regardless of the lipid components of liposomes (data not shown). The levels of anti-OVA IgG antibody production induced by the two different types of OVA-liposome conjugate were significantly different; OVA-PS-liposomes induced significantly higher levels of anti-OVA IgG antibody production than that observed in association with OVA-PC-liposomes at 2, 4, 5, and 6 weeks after primary immunization.




Fig. (8). Antigen presentation by macrophages pulsed with OVA-liposomes. Macrophages pre-incubated with OVA-liposomes were co-cultured with OVA-specific T-cell clones. Data represent the mean IL-2 concentration and the SE of the culture supernatant in triplicate cultures. Asterisk, significant ( $p < 0.01$ ) difference as compared with the other groups. Two asterisks, significant ( $p < 0.01$ ) difference as compared with the OVA solution.

A variety of cell surface molecules (e.g., lectin-like molecules [23], CD14 [24], scavenger receptor antagonists [25], and PS [21]), have been implicated in the recognition of apoptotic cells. Among them, PS is known to trigger the specific recognition and removal of apoptotic lymphocytes by macrophages [21], suggesting that the inclusion of PS in the lipid components of liposomes would lead to enhanced recognition by macrophages, and thereby result in an enhanced induction of the immune responses. On the other




Fig. (9). Anti-OVA IgG antibody production in mice immunized with OVA-liposome conjugates. BALB/c mice were immunized with OVA-liposome conjugates made using PC-liposomes (PC) or PS-liposomes (PS) at 0 and 4 weeks. The mice were bled weekly from the tail vein, and serum anti-OVA IgG was measured. Data represent the mean and SE of five mice per group. Asterisk, significant ( $p < 0.01$ ) difference between the PC- and PS-liposome groups.

hand, a number of reports have shown that PS possesses immunosuppressive properties, such as an inhibition of the T-cell mitogen response [26], a reduction of macrophage NO synthesis [27], the inhibition of tumor cytotoxicity by macrophages [28], and the suppression of antigen-specific antibody production when PS was orally administered [29]. However in this study, the inclusion of PS in the liposome composition significantly enhanced the induction of antigen-specific antibody production in mice immunized with antigen-liposome conjugates.

Thus, these results suggest that the inclusion of phosphatidyl serine in liposomes enhances the recognition and processing of surface-coupled liposomal antigen by macrophages and increases liposome-immune adjuvant activity.

#### ANTIGENS COUPLED TO THE SURFACE OF LIPOSOMES MADE USING UNSATURATED FATTY ACID ARE CROSS-PRESENTED TO CD8<sup>+</sup> T CELLS AND INDUCE POTENT ANTITUMOR IMMUNITY

Liposomes with differential lipid components were demonstrated to display differential adjuvant effects when antigens were chemically coupled to their surfaces [12, 17]. Here, the antigen presentation of liposome-coupled OVA was investigated *in vitro*, and it was found that OVA coupled to liposomes made using unsaturated fatty acid was presented to both CD4<sup>+</sup> and CD8<sup>+</sup> T-cells while OVA coupled to liposomes made using saturated fatty acid was presented only to CD4<sup>+</sup> T cells [16]. Splenic adherent cells of BALB/c mice were co-cultured with OVA-liposome conjugates made using liposomes with two different lipid components for 2 h, and subsequently cultured with splenic CD4<sup>+</sup> or CD8<sup>+</sup> T cells of OVA-immune BALB/c mice. As shown in Table (1), OVA-liposome conjugates made using liposomes with two different lipid components induced the production of comparable levels of IL-5 and IFN- $\gamma$  by CD4<sup>+</sup> T cells, while OVA solution with the same antigen concentration as OVA-liposome conjugates induced a much lower level of IL-5 production and no IFN- $\gamma$ . However, OVA-liposome conjugates made using "saturated" liposomes did not induce either IL-5 or IFN- $\gamma$  production by CD8<sup>+</sup> T cells, while OVA-liposome conjugates made using "unsaturated" liposomes induced a significant production of both IL-5 and IFN- $\gamma$ .

Confocal laser scanning microscopic analysis demonstrated that a portion of the OVA coupled to liposomes made

using unsaturated-, but not saturated fatty acid, received processing beyond the MHC class II compartment, suggesting that degradation of OVA might occur in the cytosol, and that the peptides generated in this manner would be presented to CD8<sup>+</sup> T cells *via* MHC class I. Macrophages expressed DM-DsRed ("M $\phi$  alone" in Fig. 10). The yellow spots in the "saturated" panel in Fig. (10) show that DQ-OVA coupled to liposomes received processing in the class II compartment. In contrast, in the "Unsaturated" panel in Fig. (10), both green and yellow spots were observed, suggesting that a portion of the DQ-OVA coupled to "unsaturated" liposomes did not receive processing in the class II compartment.


The ability to induce cross-presentation of an antigen coupled to liposomes consisting of unsaturated fatty acid was further confirmed by the *in vivo* induction of cytotoxic T lymphocytes. The cross-presentation of OVA coupled to "unsaturated" liposomes was further confirmed utilizing experiments of *in vivo* CTL induction. As shown in Fig. (11), both OVA<sub>257-264</sub> (D) and whole OVA (E) coupled to "unsaturated" liposomes successfully induced CTLs against target cells pulsed with OVA<sub>257-264</sub> but not against target cells pulsed with control NP<sub>366-374</sub>. On the other hand, a mixture of OVA<sub>257-264</sub> and "unsaturated" liposomes (B), and OVA<sub>257-264</sub> coupled to "saturated" liposomes (C) failed to induce CTLs against target cells pulsed with OVA<sub>257-264</sub>.

The ability to induce cross-presentation of an antigen coupled to liposomes consisting of unsaturated fatty acid was also confirmed by the induction of tumor eradication in mice. E.G7 tumors in mice that received combined inoculation with OVA<sub>257-264</sub>-liposome conjugates, CpG, and anti-IL-10 monoclonal antibodies were completely eradicated. In those mice, the frequency of CD8<sup>+</sup> T cells reactive with OVA<sub>257-264</sub> peptides in the context of H-2K<sup>b</sup> was significantly increased. In order to examine the effectiveness of liposome-coupled peptides *in vivo*, we performed tumor-rejecting experiments. B6 mice were injected subcutaneously with E.G7 cells transfected with OVA DNA, and solid tumors with a diameter of more than 5 mm were established around 7 to 10 days after the injection. Liposome-coupled peptides, OVA<sub>257-264</sub>, with CpG and the anti-IL-10 antibody were injected twice around the tumor mass. As shown in Fig. (12), a significant ( $p < 0.001$ ) decrease of the mean tumor diameter was observed as early as 7 days after inoculation of

**Table 1.** Cytokine Production by Splenic CD4/CD8 T-Cells of Mice Immunized with OVA After Co-Culture with OVA-Pulsed SAC

in vitro Ag	Liposomes	CD4		CD8	
		IL-5	IFN- $\gamma$	IL-5	IFN- $\gamma$
none		ND	ND	ND	ND
OVA solution		96.2 $\pm$ 12.5	ND	ND	ND
OVA-liposome	Saturated	910.2 $\pm$ 23.0	88.7 $\pm$ 45.0	ND	ND
OVA-liposome	Unsaturated	1065.5 $\pm$ 31.9	115.1 $\pm$ 28.6	163.3 $\pm$ 99.1	149.9 $\pm$ 83.8


Splenic CD4/CD8 T-cells were taken from mice immunized with OVA and were cultured with OVA-pulsed SAC. Data represent the mean cytokine concentration (pg/ml) in the culture supernatants and SE of triplicate culture. ND, not detected.



**Fig. (10).** Confocal laser scanning microscopic analysis of macrophages co-cultured with DQ-OVA-liposome conjugates. DM-DsRed-expressing macrophages were co-cultured with DQ-OVA-liposome conjugates made using “saturated” or “unsaturated” liposomes. Two hours after the onset of the culture, the macrophages were recovered and analyzed using confocal laser scanning microscopy. Macrophage alone, macrophages without co-culture with DQ-OVA-liposome conjugates. These optically merged images are representative of most cells examined by confocal microscopy. Yellow, co-localization of green (DQ-OVA received processing) and red (macrophage DM).

liposome-coupled OVA<sub>257-264</sub> with CpG and the anti-IL-10 antibody, and the tumors were completely eradicated in 12 days. In contrast, injection of CpG and the anti-IL-10 antibody with peptide solution containing the same amount of OVA<sub>257-264</sub> as liposome-coupled OVA<sub>257-264</sub> did not eradicate the established tumors. These results suggested that the liposome-coupled OVA<sub>257-264</sub> might effectively present OVA<sub>257-264</sub> to CTLs, resulting in tumor rejection.


In most APCs, exogenous antigens cannot be presented by the MHC class I pathway because the exogenous antigens are unable to gain access to the cytosolic compartment. This segregation of exogenous antigens from the class I pathway is important in preventing CTLs from killing healthy cells that have been exposed to foreign antigens but are not infected [30]. Consequently, in general, exogenous antigens do not prime CTL responses *in vivo*. However, there are several



**Fig. (11).** *In vivo* CTL induction in mice immunized with OVA-liposome conjugates. Mice were injected with 100  $\mu$ g of anti-IL-10 monoclonal antibodies and 5  $\mu$ g of CpG with PBS (A), a mixture of OVA<sub>257-264</sub> and “unsaturated” liposomes (B), OVA<sub>257-264</sub> “saturated” liposome conjugates (C), OVA<sub>257-264</sub> “unsaturated” liposome conjugates (D), and OVA “unsaturated” liposome conjugates (E). CFSE: bright cells (M2) were pulsed with OVA<sub>257-264</sub>, and CFSE dull cells (M1) were pulsed with NP<sub>366-374</sub> peptide as a control. Data represent the results of flow cytometric analysis for splenocytes from each mouse.

exceptions to this rule, reflecting an ability of the antigens to be delivered into the cytosolic compartments [31-35]. In this study, antigens coupled to liposomes consisting of unsaturated fatty acid were presented to both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Confocal laser scanning microscopic analysis demonstrated that a portion of the OVA coupled to liposomes received processing beyond the MHC class II compartment, suggesting that the degradation of OVA occurs in the cytosol, and that peptides generated in this manner would be presented to CD8<sup>+</sup> T cells *via* MHC class I. Cross-presentation induced by OVA coupled to liposomes consisting of unsaturated fatty acids was further confirmed in the *in vivo* CTL induction experiments. CTLs were successfully induced *in vivo* only when OVA or OVA<sub>257-264</sub> chemically coupled to “unsaturated” liposomes was inoculated into mice.





**Fig. (12).** Effect of peptide-liposome conjugates on the growth of the E.G7 tumor in mice. The tumor was established, and a mixture of CpG and anti-IL-10 was inoculated around the tumor mass in conjunction with liposome-coupled peptide ( $\Delta$ ), peptide solution containing the same amount of peptide as liposome-coupled peptide ( $\square$ ), or with nothing ( $\circ$ ). Asterisk,  $P < 0.001$  as compared with the mean diameter of the mice without inoculation of liposome-coupled peptides. Data represent the mean and SE of four mice per group.

We next investigated the ability of antigen-liposome conjugates to induce antitumor immunity. The aim of cancer vaccination is to generate an immune-mediated anti-tumor associated antigen (TAA) response resulting in the elimination of the tumor. The antigen of choice may be the whole protein alone or with immune stimulatory components, or defined epitopes (e.g., peptides) of the target antigen [36]. Recent preclinical studies have demonstrated that combined therapies involving the use of vaccines with cytokines, activators of DCs such as TLR ligands or mAb to CD40, or recombinant vectors that provide a stimulus to the innate immune system resulted in enhanced antitumor responses [37]. In the present study, antigenic peptides were chemically coupled to the surface of liposomes and inoculated into tumor-bearing mice in combination with CpG and anti-IL-10 monoclonal antibodies. This treatment successfully induced eradication of the tumor mass, whereas the inoculation of mice with CpG and anti-IL-10 monoclonal antibodies with peptide solution containing the same amount of OVA<sub>257-264</sub> as liposome-coupled OVA<sub>257-264</sub> did not affect E.G7 tumor growth (Fig. 12). It has been reported that CpG and the anti-IL-10 receptor antibody reverse tumor-induced DC paralysis, resulting in tumor rejection by CTL activated by the DC [38].

Thus, the results obtained in these experiments suggest that, by choosing lipid components for liposomes, surface-coupled liposomal antigens might be applicable for the development of tumor vaccines to present tumor antigens to APCs and induce antitumor responses.

## CONCLUSIONS AND FUTURE PERSPECTIVES

We have investigated the potential of surface-linked liposomal antigens for application to vaccine development,

in contrast to previous investigations on liposome-based drug-delivery systems, which have focused on the encapsulation of antigens into liposomes [7, 39]. During the course of this investigation, several advantages of the liposome-coupled antigens over the liposome-encapsulated antigens became apparent. (i) A predominant coupling efficiency of antigens to liposomes; following our previously reported procedure [11] for coupling antigens to liposomes, approximately 50% of the antigens bound to the surface of liposomes, whereas in the antigen-encapsulation, a 60-fold higher volume of antigens was required to obtain the same amount of conjugates (unpublished observation). (ii) Antigen-specific and IgE-selective unresponsiveness induced by surface-linked liposomal antigens; antigens chemically coupled to the surface of liposomes induced antigen-specific IgG but not IgE antibody production in mice [10] and also in monkeys [40], suggesting the potential of surface-linked liposomal antigens for application to the development of vaccines with minimal allergic side-effects. In addition, during the course of an investigation intended to clarify the mechanism of IgE-selective unresponsiveness induced by surface-linked liposomal antigen, we found the existence of an alternative mechanism, not involving T cells, in the regulation of IgE synthesis [13]. (iii) An enhanced recognition of liposomal antigens by APCs; since liposomes basically consist of immunologically inert fatty acid, they are hardly recognized by APCs. Therefore, some contrivance, such as the introduction of mannose on the surface of liposomes [41], is required in antigen-encapsulated liposomes to enhance the recognition of liposomes by APCs. On the other hand, in surface-linked liposomal antigens, antigens expressed on the surface of liposomes might be recognized more efficiently by APCs, which might result in an enhanced presentation to T cells. In fact, surface-linked liposomal antigens induced a significantly higher level of antigen-specific IgG production than that by liposome-encapsulated antigens in mice (unpublished observation). In addition, a significant difference, which correlated closely with the adjuvant activity of liposomes, was observed in the recognition of liposomal antigens by APCs between liposomes with different lipid components; more antigens coupled to the "unsaturated" liposomes were engulfed by macrophages *in vitro* and a higher level of antigen-specific antibody production was induced *in vivo* than when "saturated" liposomes were used, suggesting that the adjuvant effects of liposomes are exerted at the beginning of the immune response, i.e., upon the recognition of antigens by APCs [17]. In addition to this "quantitative" difference between liposomes with differential lipid components, a "qualitative" difference (i.e., a differential ability to induce cross-presentation) was also observed between "saturated" and "unsaturated" liposomes. Although the precise mechanism underlying this difference is currently unclear, the significant difference in membrane mobility observed between these liposomes [12] might affect their ability to induce cross-presentation. These data suggest that differential lipid components in liposomes lead to differential processing and presentation of liposomal antigens in APCs.

Taken together, these results indicate that surface-linked liposomal antigens may be applicable for the development of vaccines which induce minimal allergic reaction and virus

vaccines which induce CTL responses, and for the development of a drug which induces potent antitumor immunity.

## REFERENCES

- [1] Audibert, F. M.; Lise, D. *Immunol. Today*, **1993**, *14*, 281.
- [2] Mark, A.; Bjorksten, B.; Granstrom, M. *Vaccine*, **1995**, *13*, 669.
- [3] Gregoriadis, G. *Immunol. Today*, **1990**, *11*, 89.
- [4] Alving, C. R.; Koulchin, V.; Glenn, G. M.; Rao, M. *Immunol. Rev.*, **1995**, *145*, 5.
- [5] De Haan, A.; Tomee, J. F. C.; Huchshorn, J. P.; Wilschut, J. *Vaccine*, **1995**, *13*, 1320.
- [6] Gluck, R. *Pharm. Biotechnol.*, **1995**, *6*, 325.
- [7] Gregoriadis, G. *Immunometh.*, **1994**, *4*, 210.
- [8] Shahum, E.; Therien, H. M. *Immunol.*, **1988**, *65*, 315.
- [9] Fortin, A.; Shaum, E.; Krzystyniak, K.; Therien, H. M. *Cell. Immunol.*, **1996**, *169*, 208.
- [10] Naito, S.; Horino, A.; Nakayama, M.; Nakano, Y.; Nagai, T.; Mizuguchi, J.; Komuro, K.; Uchida, T. *Int. Arch. Allergy Immunol.*, **1996**, *109*, 223.
- [11] Nakano, Y.; Mori, M.; Nishinohara, S.; Takita, Y.; Naito, S.; Horino, A.; Kato, H.; Taneichi, M.; Komuro, K.; Uchida, T. *Int. Arch. Allergy Immunol.*, **1999**, *120*, 199.
- [12] Nakano, Y.; Mori, M.; Nishinohara, S.; Takita, Y.; Naito, S.; Kato, H.; Taneichi, M.; Komuro, K.; Uchida, T. *Bioconjugate Chemistry*, **2001**, *12*, 391.
- [13] Taneichi, M.; Naito, S.; Kato, H.; Tanaka, Y.; Mori, M.; Nakano, Y.; Yamamura, H.; Ishida, H.; Komuro, K.; Uchida, T. *J. Immunol.*, **2002**, *169*, 4246.
- [14] Uchida, T. *Curr. Drug Targ.*, **2003**, *3*, 119.
- [15] Uchida, T. *Drugs Today*, **2003**, *39*, 673.
- [16] Taneichi, M.; Ishida, H.; Kajino, K.; Ogasawara, K.; Tanaka, Y.; Kasai, M.; Mori, M.; Nishida, M.; Yamamura, H.; Mizuguchi, J.; Uchida, T. *J. Immunol.*, **2006**, *177*, 2324.
- [17] Tanaka, Y.; Kasai, M.; Taneichi, M.; Naito, S.; Kato, H.; Mori, M.; Nishida, M.; Maekawa, N.; Yamamura, H.; Komuro, K.; Uchida, T. *Bioconjug. Chem.*, **2004**, *15*, 35.
- [18] Nakano, Y.; Mori, M.; Yamamura, H.; Naito, S.; Kato, H.; Taneichi, M.; Tanaka, Y.; Komuro, K.; Uchida, T. *Bioconjug. Chem.*, **2002**, *13*, 744.
- [19] Green, S.; Fortier, J. D.; Madsen, J.; Swartz, G.; Einck, L.; Gubish, E.; Nacy, C. In *Immunology of Proteins and Peptides VIII*, M. Z. Atassi, G. S. Bixler, Ed.; Plenum Press: New York, **1995**; pp. 83-92.
- [20] Corry, D. B.; Kheradmand, F. *Nature*, **1999**, *402*, B18.
- [21] Fadok, V. A.; Bratton, D. L.; Rose, D. M.; Pearson, A.; Ezekewitz, R. A.; Henson, P. M. *Nature*, **2000**, *405*, 85.
- [22] Mori, M.; Nishida, M.; Maekawa, N.; Yamamura, H.; Tanaka, Y.; Kasai, M.; Taneichi, M.; Uchida, T. *Int. Arch. Allergy Immunol.*, **2005**, *136*, 83.
- [23] Duvall, E.; Wyllie, A. H.; Morris, R. G. *Immunol.*, **1985**, *56*, 351.
- [24] Devitt, A.; Monfatti, O. D.; Raykundalia, C.; Capra, J. D.; Simmons, D. L.; Gregory, C. D. *Nature*, **1998**, *392*, 505.
- [25] Platt, N.; Suzuki, H.; Kurihara, Y.; Kodama, T.; Gordon, S. *Proc. Natl. Acad. Sci. USA*, **1996**, *93*, 12456.
- [26] Ponzin, D.; Mancini, C.; Toffan, G.; Bruni, G.; Doria, G. *Immunopharmacology*, **1989**, *18*, 167.
- [27] Phillips, N. C.; Gagné, L. M. *J. Drug Target*, **1995**, *3*, 137.
- [28] Daemen, T.; Regts, J.; Scherphof, G. L. *Biochim. Biophys. Acta*, **1996**, *1285*, 219.
- [29] Carr, D. J.; Guarcello, V.; Blalock, J. E. *Proc. Soc. Exp. Biol. Med.*, **1992**, *200*, 548.
- [30] Rock, K. L. *Immunol. Today*, **1996**, *17*, 131.
- [31] Carbone, F. R.; Bevan, M. J. *J. Exp. Med.*, **1990**, *171*, 377.
- [32] Liu, T.; Zhou, X.; Orvell, C.; Leferer, E.; Ljunggren, H. G.; Jondal, M. *J. Immunol.*, **1995**, *154*, 3147.
- [33] Zinkernagel, R. M. *Eur. J. Immunol.*, **2002**, *32*, 2385.
- [34] Houde, M.; Berholet, F.; Gagnon, E.; Brunet, S.; Goyette, G.; Laplante, A.; Princlotta, M. F.; Thibault, P.; Sacks, D.; Desjardins, M. *Nature*, **2003**, *425*, 402.
- [35] Ackerman, A. L.; Cresswell, P. *Nature Immunol.*, **2004**, *5*, 678.
- [36] Blattman, J. N.; Greenberg, P. D. *Science*, **2004**, *305*, 200.
- [37] Dermine, S.; Gilham, D. E.; Shaw, D. M.; Davidson, E. J.; Mcziane, E. K.; Armstrong, A.; Hawkins, R. E.; Stern, P. *Biochim. Biophys. Acta*, **2004**, *1704*, 11.
- [38] Vicari, A. P.; Chiodoni, C.; Vaure, C.; Ait-Yahia, S.; Dercamp, C.; Matsos, F.; Reynard, O.; Taverne, C.; Merle, P.; Colombo, M. P.; O'Garra, A.; Trinchieri, G.; Caux, C. *J. Exp. Med.*, **2002**, *196*, 541.
- [39] Phillips, N. C.; Gagne, L.; Ivanoff, N.; Riveau, G. *Vaccine*, **1996**, *14*, 898.
- [40] Suzuki, Y.; Ami, Y.; Nagata, N.; Naito, S.; Kato, H.; Taneichi, M.; Takahashi, M.; Komiya, T.; Satoh, S.; Gondaira, F.; Sugiyama, J.; Nakano, Y.; Mori, M.; Komuro, K.; Uchida, T. *Int. Arch. Allergy Immunol.*, **2002**, *127*, 294.
- [41] Garcon, N.; Gregoriadis, G.; Taylor, M.; Summerfield, J. *Immunology*, **1988**, *64*, 743.

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

Vaccine 25 (2007) 4914–4921

[www.elsevier.com/locate/vaccine](http://www.elsevier.com/locate/vaccine)

## Peptides coupled to the surface of a kind of liposome protect infection of influenza viruses

Tomoya Nagata<sup>a,1</sup>, Toshiaki Toyota<sup>a,1</sup>, Hirohito Ishigaki<sup>a</sup>, Toru Ichihashi<sup>b</sup>,  
Kiichi Kajino<sup>b</sup>, Yoshitaka Kashima<sup>a</sup>, Yasushi Itoh<sup>a</sup>, Masahito Mori<sup>c</sup>,  
Hiroshi Oda<sup>c</sup>, Hiroyuki Yamamura<sup>c</sup>, Maiko Taneichi<sup>d</sup>,  
Tetsuya Uchida<sup>d</sup>, Kazumasa Ogasawara<sup>a,b,\*</sup>

<sup>a</sup> Department of Pathology, Shiga University of Medical Science, Ohtsu 520-2192, Japan<sup>b</sup> Department of Collaboration and Education, Research Center for Zoonosis Control, Hokkaido University, Sapporo 060-0818, Japan<sup>c</sup> Drug Delivery System Development Division, Nippon Oil and Fat Corporation, Tokyo 150-6019, Japan<sup>d</sup> Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Tokyo 208-0011, Japan

Received 8 December 2006; received in revised form 24 February 2007; accepted 4 April 2007

Available online 20 April 2007

### Abstract

In our previous study, OVA conjugated on the surface of a liposome, we termed Oleoyl liposome, which consisted of dioleoyl phosphatidyl choline, dioleoyl phosphatidyl ethanolamine, dioleoyl phosphatidyl glycerol acid and cholesterol in a 4:3:7:2 molar ratio, induced OVA-specific IgG antibody production but not OVA-specific IgE antibody production that is detrimental to the host. Furthermore, OVA<sub>257–264</sub>–Oleoyl liposome elicited CTL responses in the presence of CpG and rejected E.G7 tumors in mice. In this study we tested whether a peptide–Oleoyl liposome conjugates are capable of inducing protection against viral growth. Subcutaneous inoculation of NP<sub>366–374</sub>–Oleoyl liposome with CpG inhibited growth of influenza viruses in lungs of mice. Thus, surface-linked liposomal peptide might serve as an effective vaccine without detrimental effects in the presence of immune potentiators.

© 2007 Elsevier Ltd. All rights reserved.

**Keywords:** CTL; Peptide; Vaccine; Liposome

### 1. Introduction

Liposomes have been extensively used as delivery systems or adjuvant for vaccine antigens against bacterial [1,2]

and viral [3,4] infections and tumors [5,6]. The reason for such extensive usage is that liposomes protect antigens from degradation, and epitopic peptides encapsulated in liposomes can be easily phagocytosed by antigen-presenting cells and transferred into the classical MHC class I pathway via the phagosome-cytosol pathway [7–9]. Thus, liposomes are thought to provide peptide vaccines even in mucosal tissues.

Most of the liposomal vaccines proposed have been prepared by antigen entrapment within the aqueous lumen of liposomes. However, it is known that immune responses induced by encapsulated liposomal antigens are different from those induced by surface-linked liposomal antigens. We have demonstrated that surface-linked liposomal antigens

**Abbreviations:** CFSE, carboxyfluorescein diacetate succinimidyl ester; CTL, cytotoxic T lymphocyte; CpG, cytosine-phosphate-guanine; OVA, ovalbumin; MDCK, Madin–Darby canine kidney; NP, nucleoprotein; PFU, plaque-forming units; TLR, toll-like receptor

\* Corresponding author at: Department of Pathology, Shiga University of Medical Science, Ohtsu 520-2192, Japan. Tel.: +81 77 548 2172; fax: +81 77 548 2423.

E-mail address: [maruichi@belle.shiga-med.ac.jp](mailto:maruichi@belle.shiga-med.ac.jp) (K. Ogasawara).

<sup>1</sup> These authors equally contributed to the work in this paper.

0264-410X/\$ – see front matter © 2007 Elsevier Ltd. All rights reserved.  
doi:10.1016/j.vaccine.2007.04.010

induce antigen-specific IgG antibody production but not antigen-specific IgE antibody production [10]. The greater the membrane mobility in the liposomes is, the greater is the antibody production induced by antigen–liposome conjugates, although the membrane fluidity of the liposomes might not affect the induction of IgE-selective unresponsiveness [11]. Indeed, ovalbumin (OVA) conjugated on the surface of a liposome, we termed Oleoyl liposome, which consisted of dioleoyl phosphatidyl choline, dioleoyl phosphatidyl ethanolamine, dioleoyl phosphatidyl glycerol acid and cholesterol in a 4:3:7:2 molar ratio, sufficiently induced OVA-specific IgG antibody production but not OVA-specific IgE antibody production. In addition, treatment with OVA–Oleoyl liposome 1 and 3 weeks after cholera toxin-combined OVA administration also suppressed IgE antibody responses. The suppression of anti-OVA IgE antibody production by OVA–Oleoyl liposome was accompanied by a simultaneous enhancement of specific IgA and IgG (IgG1 and especially IgG2a) antibody production [12]. Thus, surface-linked liposomal antigens are expected to serve as a novel protocol for the development of vaccines to induce minimal allergic response.

A synthetic peptide is expected to be a potential vaccine candidate because it has several advantages compared with other types of vaccines [13]. First, because of their simple and small molecular structures, synthetic peptides rarely cause serious complications. Second, small peptide fragments without mutation in microorganisms can be selected to serve as vaccines. By means of rapid and frequent mutations, microorganisms, especially influenza virus or HIV, can escape from the host immune system. Thus, the second advantage is critical to circumvent the limitation resulting from the use of native proteins of microorganisms as vaccines. However, such small peptide fragments do not always induce potent immune responses in the host. A peptide vaccine should be protected against degradation *in vivo* by certain carriers (vehicles).

In our previous study, an OVA peptide, OVA<sub>257–264</sub>, conjugated on the surface of Oleoyl liposome elicited CTL responses in the presence of CpG and anti-IL10 in mice. Furthermore, this treatment rejected E.G7 tumors, generated by transducing the chicken OVA gene into the murine lymphoma cell line EL-4 [14]. In this study, we further examined the capacity for CTL activation of peptide–Oleoyl liposome in the presence of various immune potentiators (adjuvants) and compared the capacity for CTL activation with that of other liposomes carrying peptides. Subcutaneous inoculation of peptide–Oleoyl liposome in the presence of CpG elicited most effective CTL responses in mice. Furthermore, a nucleoprotein (NP) peptide derived from A/Aichi/2/68 (H3N2) influenza virus, NP<sub>366–374</sub>, conjugated on Oleoyl liposome in the presence of CpG protected against infection of the influenza virus. Collectively, the results suggest that peptide–Oleoyl liposome in the presence of some sort of immune potentiators might serve as an effective vaccine without detrimental effects, such as allergic reactions.

## 2. Materials and methods

### 2.1. Liposomes

Oleoyl liposomes, we termed, consisted of dioleoyl phosphatidyl choline, dioleoyl phosphatidyl ethanolamine, dioleoyl phosphatidyl glycerol acid, and cholesterol in a 4:3:2:7 molar ratio [11]. In some experiments, PS–Oleoyl liposomes were prepared by altering dioleoyl phosphatidyl choline to dioleoyl phosphatidyl serine in Oleoyl liposomes. The crude liposome solution was passed through a membrane filter (Nucleopore polycarbonate filter; Coster, Cambridge, MA) with a pore size of 0.2  $\mu\text{m}$ . Liposomal conjugates with peptides were prepared via disuccinimidyl suberate as described previously [15]. In addition, multilamellar liposome containing OVA peptide was prepared by mixing with peptide (100 nmol/mouse), 1.25  $\mu\text{mol}/\text{mouse}$  phosphatidylserine (Avanti Polar Lipids, Alabaster, AL), and 2.75  $\mu\text{mol}/\text{mouse}$  phosphatidylcholine (Avanti Polar Lipids) in chloroform as previously described [16]. The mixture in a glass tube was blown with  $\text{N}_2$  gas, evaporated at 40  $^\circ\text{C}$ , and aspirated for 1 h. The peptides incorporated in the multilamellar liposome that adhered to the inside of the glass tube were dissolved in 50  $\mu\text{l}$  of PBS by vortex mixing.

### 2.2. Immunization

C57BL/6 mice (B6) (6–10 weeks old) were obtained from Japan SLC, Inc. (Hamamatsu, Japan). CpG5002 (5'-TCCATGACGTTCTGATGTT-3', Hokkaido System Science, Sapporo, Japan) (5–10  $\mu\text{g}/\text{mouse}$ ) [17] and various peptides conjugated on Oleoyl liposome (0.6 mg/ml) in 100  $\mu\text{l}$  saline were subcutaneously inoculated into mice. Peptides used in this study were OVA<sub>257–264</sub> (SIINFEKL), NP<sub>366–374</sub> (ASNENMDAM) of an H3N2 influenza virus, NP<sub>366–374</sub> (ASNENMETM) of an H1N1 influenza virus, VSV-NP<sub>52–59</sub> (RGYVFFQGL) or LCMV-NP<sub>396–404</sub> (FQPQNGQFI). In some experiments, LPS (10  $\mu\text{g}/\text{mouse}$ ) (Wako Pure Chemical Ind., Osaka, Japan), Flagellin (10  $\mu\text{g}/\text{mouse}$ ) (Calbiochem, Darmstadt, Germany) or Poly(I:C) (10  $\mu\text{g}/\text{mouse}$ ) (Invivogen, San Diego, CA) were used as an adjuvant instead of CpG. Since all experiments were performed with the approval of the Shiga University of Medical Science Animal Experiment Committee, we usually used three mice in each group of experiments to reduce number of experimental animals.

### 2.3. *In vivo* CTL assay

Spleen cells ( $2 \times 10^7$  cells/ml) from naïve B6 mice were incubated with 0.5  $\mu\text{M}$  peptide for 2 h at 37  $^\circ\text{C}$ . After washing twice with HBSS, the recovered cells ( $2 \times 10^7$  cells/ml) were labeled with different concentrations of carboxyfluorescein diacetate succinimidyl ester (CFSE) (0.25  $\mu\text{M}$  or 2.5  $\mu\text{M}$ , Molecular Probes, Eugene, OR) at room temperature for 10 min. Labeling was stopped with one